http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Novavax Reports Third Quarter 2019 Financial Results
-
Novavax Reports Third Quarter 2019 Financial Results
-
Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 7, 2019
-
Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 7, 2019
-
Novavax (NVAX) Commences Pivotal Phase 3 Clinical Trial of NanoFlu Influenza Vaccine in Older Adults
-
Novavax Initiates Pivotal Phase 3 Clinical Trial of NanoFlu Influenza Vaccine in Older Adults
-
Novavax Initiates Pivotal Phase 3 Clinical Trial of NanoFlu Influenza Vaccine in Older Adults
-
Novavax to Present at the Ladenburg Thalmann 2019 Healthcare Conference
-
Novavax to Present at the Ladenburg Thalmann 2019 Healthcare Conference
-
Novavax to Present at the H.C. Wainwright 21st Annual Global Investment Conference
-
Novavax to Present at the H.C. Wainwright 21st Annual Global Investment Conference
-
Novavax (NVAX) Highlights New Data from Novavax Phase 3 Prepare Trial of ResVax at 2019 IDSOG Meetings
-
New Data from Novavax Phase 3 Prepare™ Trial of ResVax™ Presented at 2019 IDSOG Annual Meeting
-
New Data from Novavax Phase 3 Prepare™ Trial of ResVax™ Presented at 2019 IDSOG Annual Meeting
-
Novavax Scientific Leadership to Present New RSV Maternal Immunization Program Phase 3 Data and Participate in Discussion on RSV at the 2019 IDSOG Annual Meeting
-
Novavax Scientific Leadership to Present New RSV Maternal Immunization Program Phase 3 Data and Participate in Discussion on RSV at the 2019 IDSOG Annual Meeting
-
Novavax Reports Second Quarter 2019 Financial Results
-
Novavax Reports Second Quarter 2019 Financial Results
-
Novavax Reports Second Quarter 2019 Financial Results
-
Novavax (NVAX) Reaches Agreement with the FDA on Pivotal Phase 3 Trial Design for NanoFlu
-
Novavax Reaches Agreement with the FDA on Pivotal Phase 3 Trial Design for NanoFlu
-
Novavax Reaches Agreement with the FDA on Pivotal Phase 3 Trial Design for NanoFlu
-
Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 7, 2019
-
Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 7, 2019
-
Novavax and Catalent Announce Closing of Strategic Partnership
-
Novavax and Catalent Announce Closing of Strategic Partnership
-
Novavax (NVAX) and Catalent Biologics Enter Strategic Partnership
-
Novavax (NVAX) Confirms Accelerated Approval Pathway Available for Licensure of NanoFlu
-
Novavax Confirms Accelerated Approval Pathway Available for Licensure of NanoFlu™
-
Novavax Confirms Accelerated Approval Pathway Available for Licensure of NanoFlu™
-
Novavax and Catalent Biologics Enter Strategic Partnership: Allowing Catalent Biologics to Expand Gene Therapy Footprint with Acquisition of Novavax’ Manufacturing Assets and Capabilities
-
Novavax and Catalent Biologics Enter Strategic Partnership: Allowing Catalent Biologics to Expand Gene Therapy Footprint with Acquisition of Novavax’ Manufacturing Assets and Capabilities
-
Novavax (NVAX) Provides Updates on Global Pathways to Licensure for ResVax
-
Novavax Provides Updates on the Global Pathways to Licensure for ResVax™
-
Novavax Provides Updates on the Global Pathways to Licensure for ResVax™
-
Novavax CFO John Trizzino to Discuss Future of Influenza Vaccines on Industry Panel at 2019 BIO International Convention
-
Novavax CFO John Trizzino to Discuss Future of Influenza Vaccines on Industry Panel at 2019 BIO International Convention
-
Novavax Announces Adjustment of Conversion Rate for its 3.75% Convertible Senior Notes due 2023
-
Novavax Announces Adjustment of Conversion Rate for its 3.75% Convertible Senior Notes due 2023
-
Novavax Announces Reverse Stock Split of Common Stock
-
Novavax Announces Reverse Stock Split of Common Stock
-
Novavax Reports First Quarter 2019 Financial Results
-
Novavax Reports First Quarter 2019 Financial Results
-
Novavax Announces Presentation of Phase 3 Data from RSV Maternal Immunization Program at 37th Annual Meeting of the European Society for Pediatric Infectious Diseases
-
Novavax Announces Presentation of Phase 3 Data from RSV Maternal Immunization Program at 37th Annual Meeting of the European Society for Pediatric Infectious Diseases
-
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 2, 2019
-
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 2, 2019
-
Novavax (NVAX) to Present RSV Maternal Immunization Program Phase 3 Data and Participate in Panel on COPD
-
Novavax Scientific Leadership to Present RSV Maternal Immunization Program Phase 3 Data and Participate in Panel on COPD at World Vaccine Congress
-
Novavax Scientific Leadership to Present RSV Maternal Immunization Program Phase 3 Data and Participate in Panel on COPD at World Vaccine Congress

